Ephylone

Individuals with structural heart disease, conduction abnormalities, uncontrolled hypertension, or other cardiovascular conditions face elevated risk of arrhythmia, hypertensive emergency, and cardiovascular collapse. Tachycardia was the most common cardiovascular finding in published case series.

Individuals with epilepsy or other seizure disorders face increased risk of seizure provocation. No ephylone-specific seizure data exist, but seizures are documented in the broader synthetic cathinone class (Daziani et al. 2023 systematic review).

Individuals with significant hepatic impairment may experience prolonged or intensified effects due to reduced metabolic clearance. CYP isoform involvement is inferred (CYP2D6, CYP3A4, CYP1A2) from structural analogy with methylone and MDPV but not confirmed for ephylone specifically.

Conditions or environments that predispose to hyperthermia — including hot ambient temperatures, dehydration, vigorous physical exertion, and malignant hyperthermia susceptibility — increase the risk of dangerous hyperthermic toxicity. Animal data show sex-dependent hyperthermia vulnerability (males more affected in mouse models).

Ephylone has not been studied in pregnant or lactating individuals. No reproductive toxicity data exist in any species. Given the compound's potent catecholaminergic activity and documented cardiovascular and hyperthermic toxicity, exposure during pregnancy or lactation cannot be considered safe.

Concurrent use of MAO inhibitors (irreversible or reversible) with ephylone carries risk of fatal hypertensive crisis and serotonin syndrome via synergistic monoamine potentiation. No ephylone-specific case report exists, but the mechanism is well-established for the cathinone and stimulant drug classes.

Concurrent use of serotonergic medications (SSRIs, SNRIs, triptans, lithium, linezolid) with ephylone increases the risk of serotonin syndrome. The serotonin syndrome risk for the synthetic cathinone class has been confirmed by systematic review (Daziani et al. 2023).